Trial Profile

Phase 3 trial of ELI-002 in patients with KRAS-mutated pancreatic adenocarcinoma

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 03 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ELI 002 (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Registrational; Therapeutic Use

Most Recent Events

31 Mar 2025 According to Elicio Therapeutics media release, the company is Potential to finalize this pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in H2 2025.
30 Jan 2025 New trial record
22 Jan 2025 According to Elicio Therapeutics media release,the company announced that it would expect to file a Biologics License Application (BLA) if supported by a planned Phase 3 trial.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com